Specialitiy
Spotlight

   




 

Dermatology & Venereology

 

     




Hair
Disorder

      

  • Lotufo PA, Chae CU, Ajani UA, et al (Harvard Med School, Boston)

    Male Pattern Baldness and Coronary Heart Disease: The Physicians’ Health Study 

    Arch Intern Med 160: 165-171, 2000

        

    Male pattern baldness (MPB) and coronary heart disease (CHD) are noticed around 45 years of age. Increase in the incidence of the latter is directly related to the spread of baldness from the frontal region to the vertex in subsequent years. Androgens are expected to cause hyperlipidemia, atherosclerosis and CHD as well as MPB.

        

    The authors conclude that heredity may be an additional factor.

         
  • Hirsutism 

    Moghetti P, Tosi F, Tosti A, et al (Univ of Verona, Italy; Univ of Bologna, Italy; Ospedale Maggiore, Verona, Italy)

    Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial 

    J Clin Endocrinol Metab 85: 89-94, 2000

         


    In this study 40 hirsute women were treated with 100 mg/d of spironolactone or 5mg/d of finasteride or 250 mg/d of flutamide or a placebo.

        


    At the end of 6 months the authors found an improvement in all on active treatment. Reduced hair diameter was found in hair from the linea alba.

       
  • Hirsutism – recurrence 

    Yucelten D, Erenus M, Gurbuz O, et al (Marmara Univ, Istanbul, Turkey)

    Recurrence Rate of Hirsutism After 3 Different Antiandrogen Therapies 

    J Am Acad Dermatol 41:64-68, 1999

        


    Hirsute women (n=81) received 1 of 3 schedules; spironolactone 100 mg/d with an oral contraceptive or an oral contraceptive and cyproterone acetate 50 mg/day (day 1 to 10 of the menstrual cycle) or 250 mg bid of flutamide.

        


    Treatment lasted till clearance of the hirsute state.

       


    Compared to the baseline fall in levels of testosterone and luteinizing hormone in the serum were recorded.

       


    At the end of 1 year of stopping treatment the authors noted all parameters to be at the pretreatment levels.

          
  • Liew SH, Grobbelaar AO, Gault D, et al (Mount Vernon Hosp, Northwood, England)

    Ruby Laser-Assisted Hair Removal: A Preliminary Report of the Correlation Between Efficacy of Treatment and Melanin Content of Hair and the Growth Phases of Hair at a Specific Site 

    Ann Plast Surg 42: 255-258, 1999

        

    The authors have tried to evaluate the results of laser hair removal at clinically determined different phases of hair cycle. All participants were white with black hair.

         

    One group received a single dose of 11 J/cm2 on the legs. The second group showing the best results was treated once a month with a dose between 10.5 to 14.5 J/cm2. Evaluation was carried out at the end of 3 months.

         

    Highly pigmented hair seemed to respond better. One subject developed a crusted skin lesion. 

         
  • Hair Removal 

    Schroeter CA, Raulin C, Thurlimann W, et al (Med Centre Maastricht, The Netherlands; Karlsruhe, Germany; Univ Hosp Aachen, Germany; et al)

    Hair removal in 40 Hirsute Women With an Intense Laser-Like Light Source

    Eur J Dermatol 9: 374-379, 1999

          

    Photothermolysis is exploited in this procedure. Unlike laser the light is incoherent in a spectrum of 500-1200 nm and thus adjustable during treatment, depending on the structures being eliminated.

         

    PhotoDerm VL (ESC Medical Systems Ltd, Yonkeam, Israel) is mentioned by the authors. The system also requires a cooling gel on the skin and filters that allow adjustment for skin type of the subject thus adding selectivity to the process. 

         

    Stinging sensation, erythema and edema are described as is dyspigmentation. Blond hair need more sessions than the black. Microscopic partial follicular damage, hair shrinkage and break at the epidermal surface are recorded by the authors.

         


 



 

    

Specialitiy Spotlight

   

     

Hair Disorder
      

  • Lotufo PA, Chae CU, Ajani UA, et al (Harvard Med School, Boston)
    Male Pattern Baldness and Coronary Heart Disease: The Physicians’ Health Study 
    Arch Intern Med 160: 165-171, 2000
        
    Male pattern baldness (MPB) and coronary heart disease (CHD) are noticed around 45 years of age. Increase in the incidence of the latter is directly related to the spread of baldness from the frontal region to the vertex in subsequent years. Androgens are expected to cause hyperlipidemia, atherosclerosis and CHD as well as MPB.
        
    The authors conclude that heredity may be an additional factor.
         
  • Hirsutism 
    Moghetti P, Tosi F, Tosti A, et al (Univ of Verona, Italy; Univ of Bologna, Italy; Ospedale Maggiore, Verona, Italy)
    Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial 
    J Clin Endocrinol Metab 85: 89-94, 2000
         
    In this study 40 hirsute women were treated with 100 mg/d of spironolactone or 5mg/d of finasteride or 250 mg/d of flutamide or a placebo.
        
    At the end of 6 months the authors found an improvement in all on active treatment. Reduced hair diameter was found in hair from the linea alba.
       
  • Hirsutism – recurrence 
    Yucelten D, Erenus M, Gurbuz O, et al (Marmara Univ, Istanbul, Turkey)
    Recurrence Rate of Hirsutism After 3 Different Antiandrogen Therapies 
    J Am Acad Dermatol 41:64-68, 1999
        
    Hirsute women (n=81) received 1 of 3 schedules; spironolactone 100 mg/d with an oral contraceptive or an oral contraceptive and cyproterone acetate 50 mg/day (day 1 to 10 of the menstrual cycle) or 250 mg bid of flutamide.
        
    Treatment lasted till clearance of the hirsute state.
       
    Compared to the baseline fall in levels of testosterone and luteinizing hormone in the serum were recorded.
       
    At the end of 1 year of stopping treatment the authors noted all parameters to be at the pretreatment levels.
          
  • Liew SH, Grobbelaar AO, Gault D, et al (Mount Vernon Hosp, Northwood, England)
    Ruby Laser-Assisted Hair Removal: A Preliminary Report of the Correlation Between Efficacy of Treatment and Melanin Content of Hair and the Growth Phases of Hair at a Specific Site 
    Ann Plast Surg 42: 255-258, 1999
        
    The authors have tried to evaluate the results of laser hair removal at clinically determined different phases of hair cycle. All participants were white with black hair.
         
    One group received a single dose of 11 J/cm2 on the legs. The second group showing the best results was treated once a month with a dose between 10.5 to 14.5 J/cm2. Evaluation was carried out at the end of 3 months.
         
    Highly pigmented hair seemed to respond better. One subject developed a crusted skin lesion. 
         
  • Hair Removal 
    Schroeter CA, Raulin C, Thurlimann W, et al (Med Centre Maastricht, The Netherlands; Karlsruhe, Germany; Univ Hosp Aachen, Germany; et al)
    Hair removal in 40 Hirsute Women With an Intense Laser-Like Light Source
    Eur J Dermatol 9: 374-379, 1999
          
    Photothermolysis is exploited in this procedure. Unlike laser the light is incoherent in a spectrum of 500-1200 nm and thus adjustable during treatment, depending on the structures being eliminated.
         
    PhotoDerm VL (ESC Medical Systems Ltd, Yonkeam, Israel) is mentioned by the authors. The system also requires a cooling gel on the skin and filters that allow adjustment for skin type of the subject thus adding selectivity to the process. 
         
    Stinging sensation, erythema and edema are described as is dyspigmentation. Blond hair need more sessions than the black. Microscopic partial follicular damage, hair shrinkage and break at the epidermal surface are recorded by the authors.
         

 

 

By |2022-07-20T16:42:28+00:00July 20, 2022|Uncategorized|Comments Off on Hair Disorders

About the Author: